People looking to lose weight and lower their blood sugar may someday be able to get a single injection that turns their ...

A novel machine learning gene risk biomarker test successfully predicted patient response to semaglutide treatment after ...

Novo Nordisk (NVO) plans to run studies on how its GLP-1 class of weight loss/diabetes drug can help people deal with addiction, Martin Holst Lange, the Danish pharma’s head of development, told an ...

Racial differences in GLP-1 concentrations in obese subjects have not been previously reported. Based on GLP-1's effect on β-cell function and insulin secretion, we assessed whether differences in GLP ...

“In people who have diabetes, when they’re on GLP-1s, they experience an early increase in the risk of diabetic retinopathy,” ...

A $350 genetic test developed by researchers at Mayo Clinic in Rochester, Minn., and subsequently licensed to Phenomic Sciences, seeks to assign risk scores to patients regarding their likelihood of ...

An investigational small-molecule, nonpeptide oral GLP-1 receptor agonist significantly reduced weight in adults with obesity in the randomized ATTAIN-1 trial. At week 72, orforglipron at multiple ...

Lexaria (NASDAQ:LEXX) said it plans to run an animal study evaluating formulations of its products DehydraTECH-GLP-1, which includes Novo Nordisk's semaglutide or liraglutide, and DehydraTECH-CBD in ...

Midwest BioResearch, LLC has announced the introduction of a microAmes screen that fully predicts the GLP regulatory Ames test (Salmonella/E. coli Mammalian Microsome Reverse Mutation Assay).

Experts from NASA are keeping a close eye on UK research that tests whether drugs commonly used in diabetes work against raised brain pressure – a painful problem sometimes seen in women with obesity ...